Claims for Patent: 5,234,811

Summary for Patent: 5,234,811

Title:	Assay for a new gaucher disease mutation
Abstract:	A method for detecting a new Gaucher disease mutation in an allele in a human having an insertion mutation of a guanine nucleotide adjacent to nucleotide position 57 in the normal glucocerebrosidase gene exon 2 is provided. Identification of the mutation is accomplished by first amplifying, with a polymerase chain reaction (PCR) primer, a region of human genomic DNA containing nucleotide positions 57 and 58 of glucocerebrosidase gene exon 2 followed by detection of the mutation.
Inventor(s):	Beutler; Ernest (La Jolla, CA), Sorge; Joseph A. (Rancho Santa Fe, CA)
Assignee:	The Scripps Research Institute (La Jolla, CA)
Application Number:	07/767,135
Patent Claims:	1. A human genetic screening method for identifying a glucocerebrosidase gene mutation comprising detecting in a nucleic acid sample isolated from a human an insertion of a guanine nucleotide adjacent to nucleotide position 57 of glucocerebrosidase gene exon 2, thereby identifying said mutation. 2. The method according to claim 1 further comprising additionally detecting in said nucleic acid sample the presence of a glucocerebrosidase gene point mutation characterized as a change from an adenine nucleotide to a guanine nucleotide at nucleotide position 2 of glucocerebrosidase gene exon 9. 3. The method according to claim 1 further comprising additionally detecting in said nucleic acid sample the presence of a glucocerebrosidase gene point mutation characterized as a change from a thymine nucleotide to a cytosine nucleotide at nucleotide position 60 of glucocerebrosidase gene exon 10. 4. A human genetic screening method for identifying a glucocerebrosidase gene insertion mutation comprising: (a) treating, under amplification conditions, a sample of genomic DNA from a human with a polymerase chain reaction (PCR) primer pair for amplifying a region of human genomic DNA containing nucleotide positions 57 and 58 of glucocerebrosidase gene exon 2, said treating producing an amplification product containing said region; and (b) detecting in the amplification product of step (a) for presence of a guanine (G) nucleotide insertion mutation after nucleotide position 57 of said exon, thereby identifying said mutation. 5. The method according to claim 4 wherein said region contains a nucleotide sequence represented by SEQ ID NO 19, or a fragment thereof. 6. The method according to claim 5 wherein said region consists essentially of a nucleotide sequence represented by SEQ ID NO 2. 7. The method according to claim 4 wherein said detecting comprises treating, under hybridization conditions, the amplification product of step (a) with an oligonucleotide probe specific for said insertion mutation, and detecting the formation of a hybridization product. 8. The method according to claim 7 wherein said oligonucleotide probe contains a nucleotide sequence represented by the formula, 5'-ACAGGATTGGCTCTACT-3' (SEQ ID NO 5). 9. The method according to claim 4 wherein said PCR primer pair produces an amplification product containing a preselected restriction enzyme site if said mutation is present, and said detecting of step (b) comprises treating, under restriction conditions, the amplification product of step (a) with a restriction enzyme that recognizes said site, and detecting the presence of restriction products. 10. The method according to claim 4 wherein said PCR primer pair comprises: (i) a first primer that hybridizes to an anti-sense strand of said exon 2 at a location 5' to nucleotide 57 of said exon; and (ii) a second primer that hybridizes to a sense strand of said exon 2 at a location 3' to nucleotide 56 of said exon. 11. The method according to claim 10 wherein said first primer of step (i) is represented by the formula, 5'-GAATGTCCCAAGCCTTTGA-3' (SEQ ID NO 3). 12. The method according to claim 10 wherein said second primer of step (ii) is represented by the formula, 5'-CACTGCCTGAAGTAGATGC-3' (SEQ ID NO 4). 13. The method according to claim 10 wherein said second primer encodes a preselected restriction endonuclease site, and step (b) comprises treating the amplification product of step (a) with a restriction endonuclease that recognizes said preselected restriction site. 14. The method according to claim 11 wherein said restriction endonuclease i Bsa BI and said preselected restriction site is represented by the formula: 15. A method for detecting in a human a Gaucher disease allele containing an insertion mutation comprising insertion of a guanine (G) nucleotide after nucleotide position 57 of glucocerebrosidase gene exon 2, which method comprises: (a) forming a polymerase chain reaction (PCR) admixture by combining, in a PCR buffer, a sample of genomic DNA from said human and a glucocerebrosidase gene-specific PCR primer pair defined by 3' and 5' primers, said 3' primer priming within a region of human genomic DNA corresponding to nucleotide position 1-20 of glucocerebrosidase gene intron 2, and said 5' primer priming within a region of human genomic DNA corresponding to nucleotide positions 1-57 of said glucocerebrosidase gene; (b) subjecting said PCR admixture to a plurality of PCR thermocycles to produce a glucocerebrosidase gene amplification product; (c) treating, under hybridization conditions, said amplification product with an oligonucleotide probe specific for said insertion mutation; and (d) detecting hybridization products produced in step (c), thereby detecting said mutation. 16. The method according to claim 15 wherein said 5' primer of step (a) is represented by the formula, 5'-GAATGTCCCAAGCCTTTGA-3' (SEQ ID NO 3). 17. The method according to claim 15 wherein said 3' primer of step (a) is represented by the formula, 5'-CACTGCCTTGACTCACTCAC-3' (SEQ ID NO 7). 18. The method according to claim 15 wherein said probe of step (c) is represented by the formula, 5'-ACAGGATTGGCTTCTACT-3' (SEQ ID NO 5). 19. A human genetic screening method for identifying preselected glucocerebrosidase gene mutations comprising: (a) treating, under amplification conditions, a sample of genomic DNA from a human with a polymerase chain reaction (PCR) primer pair for amplifying a region of human genomic DNA containing nucleotide positions 57 and 58 of glucocerebrosidase gene exon 2, said treating producing a first amplification product containing said region; and (b) treating, under amplification conditions, a sample of genomic DNA from said human with a polymerase chain reaction (PCR) primer pair for amplifying a region of human genomic DNA containing nucleotide position 2 of glucocerebrosidase gene exon 9 and nucleotide position 60 of glucocerebrosidase exon 10, said treating producing a second amplification product containing said region; (c) detecting in said first amplification product of step (a) the presence of a guanine nucleotide insertion mutation after nucleotide position 57 of said exon; (d) detecting in said second amplification product of step (b) the presence of a guanine nucleotide point mutation at nucleotide position 2 of said exon; and (e) detecting in said second amplification product of step (b) the presence of a cytosine nucleotide point mutation at nucleotide position 60 of said exon, thereby detecting said mutations. 20. The method according to claim 19 wherein said primer pair of step (a) comprises 5' and 3' primers, said 5' primer priming within a region of human genomic DNA corresponding to nucleotide positions 1-57 of said glucocerebrosidase gene exon 2, and said 3' primer priming within a region of human genomic DNA corresponding to nucleotide positions 1-20 of said glucocerebrosidase gene intron 2. 21. The method according to claim 20 wherein said 5' primer of step (a) is represented by the formula, 5'-GAATGTCCCAAGCCTTTGA-3' (SEQ ID NO 3). 22. The method according to claim 20 wherein said 3' primer of step (a) is represented by the formula, 5'-CACTGCCTTGACTCACTCAC-3' (SEQ ID NO 7). 23. The method according to claim 19 wherein said primer pair of step (b) comprises 5' and 3' primers, said 5' primer priming within a region of human genomic DNA corresponding to nucleotide positions 841-860 of said glucocerebrosidase gene intron 7, and said 3' primer priming within a region of human genomic DNA corresponding to nucleotide positions 26-45 of said glucocerebrosidase gene intron 10. 24. The method according to claim 23 wherein said 5' primer is represented by the formula, 5'-CAAGGTCCAGGATCAGTTGC-3' (SEQ ID NO 17). 25. The method according to claim 23 wherein said 3' primer is represented by the formula, 5'-AACGCTGTCTTCAGCCCACT-3' (SEQ ID NO 18). 26. The method according to claim 19 wherein said detecting of step (c) comprises treating, under hybridization conditions, said amplification product with an oligonucleotide probe represented by the formula, 5'-ACAGGATTGGCTTCTACT-3' (SEQ ID NO 5). 27. The method according to claim 19 wherein said detecting of step (d) comprises treating, under hybridization conditions, said amplification product with an oligonucleotide probe represented by the formula, 5'-TACCCTAGAGCCTCCTG-3' (SEQ ID NO 10). 28. The method according to claim 19 wherein said detecting of step (e) comprises treating, under hybridization conditions, said amplification product with an oligonucleotide probe represented by the formula, 5'-GAACGACCCGGACGCAG-3' (SEQ ID NO 12).

Details for Patent 5,234,811

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26